{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:03:15Z","timestamp":1785330195877,"version":"3.55.0"},"reference-count":46,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Objectives: Pleural mesothelioma (PM) is a rare cancer that often develops after a decades-long latency period and confers a grim prognosis. Novel, biomarker-based therapeutic modalities are expected to improve the outcome of patients with advanced PM. CUDC-907 (fimepinostat) is a dual inhibitor that affects both histone deacetylases and PI3K enzymes. Its antitumor activity was described in several cancer types, but it has not yet been explored in PM. Materials and Methods: The sensitivity of 22 PM cell lines\u2014including 18 models established in our laboratory\u2014to cisplatin and CUDC-907 was determined using a cell viability assay. BAP1, PTEN, and c-Myc expression, as well as MYC copy number variation, were measured. The effect of combination treatment with cisplatin was assessed with cell viability, cell cycle, and 3D spheroid formation assays. Results: Most PM cell lines were sensitive to CUDC-907 treatment, and the CUDC-907 response was significantly higher in cell lines with higher c-Myc expression due to MYC copy number gain or amplification. Importantly, all cisplatin-insensitive cell lines were sensitive to CUDC-907. Combination treatment with cisplatin synergistically decreased cell viability and induced G2\/M arrest or cell death. We tested cisplatin-sensitive P31WT and cisplatin resistant P31cis isogeneic pair and found that in both 2D and 3D assays the cisplatin-resistant cells showed a higher sensitivity to CUDC-907 single treatment. Combining CUDC-907 with cisplatin further decreased cell growth even in cisplatin-resistant cells. Conclusions: The majority of PM cell models are sensitive to CUDC-907, which may be a potent therapeutic agent in PM.<\/jats:p>","DOI":"10.3390\/cells14201599","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T08:34:26Z","timestamp":1760517266000},"page":"1599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression"],"prefix":"10.3390","volume":"14","author":[{"given":"Luca","family":"Heged\u00fcs","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7218-2694","authenticated-orcid":false,"given":"Silvia","family":"Qaisieh","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"St\u00fclpnagel","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2817-6334","authenticated-orcid":false,"given":"Yavar","family":"Ganjeh Khor Dezfouli","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winny","family":"Tambo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0878-0406","authenticated-orcid":false,"given":"Fabian","family":"Doerr","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Baldes","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Theegarten","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medicine Essen, West German Cancer Center, University Duisburg-Essen, Hufelandstra\u00dfe 55, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":false,"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medicine Essen, West German Cancer Center, University Duisburg-Essen, Hufelandstra\u00dfe 55, 45147 Essen, Germany"},{"name":"National Center for Tumor Diseases (NCT), NCT West, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8275-5957","authenticated-orcid":false,"given":"Servet","family":"B\u00f6l\u00fckbas","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"},{"name":"National Center for Tumor Diseases (NCT), NCT West, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-4153","authenticated-orcid":false,"given":"Balazs","family":"Heged\u00fcs","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen\u2014Ruhrlandklinik, West German Cancer Center, University Duisburg-Essen, T\u00fcschener Weg 40, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Jain, M., Crites, M.K., Rich, P., and Bajantri, B. (2024). Malignant Pleural Mesothelioma: A Comprehensive Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195837"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-pathol-042420-092719","article-title":"Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment","volume":"19","author":"Fanaroff","year":"2024","journal-title":"Annu. Rev. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2018.03.022","article-title":"Loss of C\/EBP-beta LIP drives cisplatin resistance in malignant pleural mesothelioma","volume":"120","author":"Kopecka","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-20-4037","article-title":"Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma","volume":"27","author":"Oehl","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Borchert, S., Suckrau, P.M., Walter, R.F.H., Wessolly, M., Mairinger, E., Steinborn, J., Hegedus, B., Hager, T., Herold, T., and Eberhardt, W.E.E. (2020). Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-75807-x"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: An open-label, dose-escalation, phase 1 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jenke, R., Ressing, N., Hansen, F.K., Aigner, A., and Buch, T. (2021). Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13040634"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1111\/jcmm.15281","article-title":"CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action","volume":"24","author":"Hu","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13046-020-01728-2","article-title":"The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer","volume":"39","author":"Ma","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1535-7163.MCT-16-0390","article-title":"Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers","volume":"16","author":"Sun","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","first-page":"639","article-title":"Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura","volume":"10","author":"Ramael","year":"1995","journal-title":"Histol. Histopathol."},{"key":"ref_15","first-page":"1724","article-title":"Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity","volume":"7","author":"Tan","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/JTO.0000000000000202","article-title":"Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma","volume":"9","author":"Riquelme","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13046-023-02678-1","article-title":"MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat","volume":"42","author":"Chen","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jian, Z., Han, Y., Zhang, W., Li, C., Guo, W., Feng, X., Li, B., and Li, H. (2022). Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1alpha-JNK-mediated cytotoxic autophagy in esophageal cancer. Cell Biosci., 12.","DOI":"10.1186\/s13578-022-00855-x"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liao, W., Yang, W., Xu, J., Yan, Z., Pan, M., Xu, X., Zhou, S., Zhu, Y., Lan, J., and Zeng, M. (2021). Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.658197"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3892\/or.2023.8567","article-title":"CUDC-907 suppresses epithelial-mesenchymal transition, migration and invasion in a 3D spheroid model of bladder cancer","volume":"49","author":"Ho","year":"2023","journal-title":"Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chilamakuri, R., and Agarwal, S. (2022). Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth. Cancers, 14.","DOI":"10.3390\/cancers14041067"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10637-023-01415-x","article-title":"Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage","volume":"42","author":"Wang","year":"2024","journal-title":"Investig. New Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/0008-5472.CAN-23-0394","article-title":"Fimepinostat Impairs NF-kappaB and PI3K\/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bjh.17730","article-title":"Fimepinostat (CUDC-907) in patients with relapsed\/refractory diffuse large B cell and high-grade B-cell lymphoma: Report of a phase 2 trial and exploratory biomarker analyses","volume":"195","author":"Landsburg","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","article-title":"CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: Results from an expanded phase I trial","volume":"102","author":"Oki","year":"2017","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/JTO.0b013e3181c5e366","article-title":"Histone deacetylase inhibitors in malignant pleural mesothelioma: Preclinical rationale and clinical trials","volume":"5","author":"Paik","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"216395","DOI":"10.1016\/j.canlet.2023.216395","article-title":"Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo","volume":"574","author":"Schelch","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hoyos, C., Fontaine, A., Jacques, J.R., Heinen, V., Louis, R., Duysinx, B., Scherpereel, A., Wasielewski, E., Jamakhani, M., and Hamaidia, M. (2022). HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Cancers, 14.","DOI":"10.3390\/cancers14092164"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13148-018-0517-9","article-title":"Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma","volume":"10","author":"Bensaid","year":"2018","journal-title":"Clin. Epigenet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101857","DOI":"10.1016\/j.tranon.2023.101857","article-title":"The highly selective and oral phosphoinositide 3-kinase delta (PI3K-delta) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition","volume":"43","author":"Kalla","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10637-021-01086-6","article-title":"Phase 1 cohort expansion study of LY3023414, a dual PI3K\/mTOR inhibitor, in patients with advanced mesothelioma","volume":"39","author":"Zauderer","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2023.03.003","article-title":"TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy","volume":"178","author":"Hegedus","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ijc.2910410210","article-title":"Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma","volume":"41","author":"Stahel","year":"1988","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2008.02.007","article-title":"alpha-Toxin of Staphylococcus aureus overcomes acquired cisplatin-resistance in malignant mesothelioma cells","volume":"265","author":"Johansson","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.bjc.6605467","article-title":"Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells","volume":"102","author":"Johansson","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4176376","DOI":"10.1155\/2020\/4176376","article-title":"Digital PCR for the Analysis of MYC Copy Number Variation in Lung Cancer","volume":"2020","author":"Brik","year":"2020","journal-title":"Dis. Markers"},{"key":"ref_40","first-page":"2.13.1","article-title":"CNV analysis using TaqMan copy number assays","volume":"2","author":"Mayo","year":"2010","journal-title":"Curr. Protoc. Hum. Genet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kubickova, A., De Sanctis, J.B., and Hajduch, M. (2023). Isoform-Directed Control of c-Myc Functions: Understanding the Balance from Proliferation to Growth Arrest. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417524"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10637-017-0501-9","article-title":"CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance","volume":"36","author":"To","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/1535-7163.MCT-24-0308","article-title":"TEAD-Independent Cell Growth of Hippo-Inactive Mesothelioma Cells: Unveiling Resistance to TEAD Inhibitor K-975 through MYC Signaling Activation","volume":"24","author":"Akao","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.18632\/oncotarget.14876","article-title":"Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma","volume":"8","author":"Mondello","year":"2017","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Liu, Y., Qi, X., Luo, X.P., Wang, Y.F., Wan, J.J., Wang, F.Z., and Zhang, W.Y. (2025). CUDC-907 exerts an inhibitory effect on non-small cell lung cancer associated with induction of mitotic catastrophe and downregulation of YAP\/TAZ signaling. Chem. Biol. Interact., 421.","DOI":"10.1016\/j.cbi.2025.111735"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1158\/1078-0432.CCR-17-1043","article-title":"Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases","volume":"23","author":"Kotian","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/20\/1599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:02:47Z","timestamp":1760518967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/20\/1599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":46,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cells14201599"],"URL":"https:\/\/doi.org\/10.3390\/cells14201599","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}